The Periodontitis drugs in development market research report provides comprehensive information on the therapeutics under development for Periodontitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Periodontitis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Periodontitis and features dormant and discontinued products.

GlobalData tracks 20 drugs in development for Periodontitis by 18 companies/universities/institutes. The top development phase for Periodontitis is preclinical with ten drugs in that stage. The Periodontitis pipeline has 16 drugs in development by companies and four by universities/ institutes. Some of the companies in the Periodontitis pipeline products market are: University of Pennsylvania, PerioTrap Pharmaceuticals and MetiMedi Pharmaceuticals.

The key targets in the Periodontitis pipeline products market include Exotoxin, Glutaminyl Peptide Cyclotransferase (Glutaminyl Cyclase or Glutaminyl tRNA Cyclotransferase or Glutamyl Cyclase or QPCT or EC 2.3.2.5), and Complement C3 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 1 or C3).

The key mechanisms of action in the Periodontitis pipeline product include Glutaminyl Peptide Cyclotransferase (Glutaminyl Cyclase or Glutaminyl tRNA Cyclotransferase or Glutamyl Cyclase or QPCT or EC 2.3.2.5) Inhibitor with one drug in Discovery. The Periodontitis pipeline products include 15 routes of administration with the top ROA being Intravenous and six key molecule types in the Periodontitis pipeline products market including Cell Therapy, and Small Molecule.

Periodontitis overview

Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, bright red or purplish gums, bad breath, and spaces developing between teeth. Risk factors include gingivitis, heredity, diabetes, age, substance abuse, and a weakened immune system.

For a complete picture of Periodontitis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.